1. Home
  2. CSTE vs BTAI Comparison

CSTE vs BTAI Comparison

Compare CSTE & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CSTE

Caesarstone Ltd.

HOLD

Current Price

$1.23

Market Cap

68.8M

Sector

Industrials

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.59

Market Cap

36.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSTE
BTAI
Founded
1987
2017
Country
Israel
United States
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.8M
36.5M
IPO Year
2012
2018

Fundamental Metrics

Financial Performance
Metric
CSTE
BTAI
Price
$1.23
$1.59
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
$5.00
$26.67
AVG Volume (30 Days)
98.8K
296.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.59
$261.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.86
$1.17
52 Week High
$3.70
$8.08

Technical Indicators

Market Signals
Indicator
CSTE
BTAI
Relative Strength Index (RSI) 26.86 45.49
Support Level $0.86 $1.50
Resistance Level $1.90 $1.72
Average True Range (ATR) 0.22 0.10
MACD -0.09 0.01
Stochastic Oscillator 2.26 24.53

Price Performance

Historical Comparison
CSTE
BTAI

About CSTE Caesarstone Ltd.

Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: